 | Up a level |
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
Regan, Meredith M.; Leyland-Jones, Brian; Bouzyk, Mark; Pagani, Olivia; Tang, Weining; Kammler, Roswitha; Dell’Orto, Patrizia; Biasi, Maria Olivia; Thürlimann, Beat; Lyng, Maria B.; Ditzel, Henrik J.; Neven, Patrick; Debled, Marc; Maibach, Rudolf; Price, Karen N.; Gelber, Richard D.; Coates, Alan S.; Goldhirsch, Aron; Rae, James M. and Viale, Giuseppe (2012). CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. Journal of the National Cancer Institute JNCI, 104(6), pp. 441-451. Oxford University Press 10.1093/jnci/djs125
